Targeting ALK Rearrangements in NSCLC: Current State of the Art
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2022.863461
Abstract: Anaplastic lymphoma kinase (ALK) alterations in non-small cell lung cancer (NSCLC) can be effectively treated with a variety of ALK-targeted drugs. After the approval of the first-generation ALK inhibitor crizotinib which achieved better results in… read more here.
Keywords: alk inhibitors; generation alk; alk rearrangements; targeting alk ... See more keywords